# Phase I BLASST-3 Trial

> **NCT04972253** · PHASE1 · WITHDRAWN · sponsor: **Guru P. Sonpavde**

## Conditions studied

- Bladder Transitional Cell Carcinoma
- Bladder Cancer
- Fibroblast Growth Factor Receptor

## Interventions

- **DRUG:** Infigratinib

## Key facts

- **NCT ID:** NCT04972253
- **Lead sponsor:** Guru P. Sonpavde
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-23
- **Primary completion:** 2022-12
- **Final completion:** 2023-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Low Accrual
- **Last updated:** 2022-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04972253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04972253, "Phase I BLASST-3 Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04972253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*